Neuros Medical, Cleveland, Ohio, has announced that its long-term pilot study indicates the company’s patented on-demand, high-frequency Electrical Nerve Block™ technology provided significant pain relief for patients with amputations who experience phantom limb pain.
Results from the U.S. Food and Drug Administration (FDA)-approved study indicate that seven out of nine subjects reported significant pain reduction, defined as 50 percent or greater, observed for up to 12 months of evaluation. The study demonstrated no safety issues over the treatment period. Study subjects reported an average pain score reduction of six to one, or 83 percent, based on a zero to ten numerical rating scale. Significant pain reduction was reported in 91 percent of all treatment sessions. In addition, more than half of the subjects discontinued their narcotic pain medication use during the study.
The study was led by Amol Soin, MD, of the Kettering Health Network Innovation Center, Ohio, and the Ohio Pain Clinic, Dayton. Study results will be shared at the International Neuromodulation Society’s 11th World Congress in Berlin, Germany, June 8-13, 2013.
